All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub was delighted to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San Francisco, US, and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US, during the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
The microbiome and its effects on the immune system
In this animated video, Christine Spencer and Diwakar Davar describe the microbiome and its effects on the immune system. The pair begin by explaining the role of the microbiome, the concept of immunosurveillance, and how the composition of the intestinal microbiota could affect the response to cancer therapy. They describe the past and present research investigating how the microbiome can be altered to support the efficacy of immunotherapies, with a focus on checkpoint inhibitors. Finally, they discuss how the microbiome can reduce immune reactions, such as graft-versus-host disease, and immunotherapy-related toxicities.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox